Patents Assigned to ChemoCentryx, Inc.
  • C5aR ANTAGONISTS
    Publication number: 20110275639
    Abstract: Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.
    Type: Application
    Filed: March 25, 2011
    Publication date: November 10, 2011
    Applicant: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Kevin Lloyd Greenman, Manmohan Reddy Leleti, Yandong Li, Jay P. Powers, Hiroko Tanaka, Ju Yang, Yibin Zeng
  • COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS
    Publication number: 20110165164
    Abstract: Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described.
    Type: Application
    Filed: December 9, 2010
    Publication date: July 7, 2011
    Applicant: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Bretton Summers, Maureen C. Howard, Thomas J. Schall, Zhenhua Miao
  • 3-(imidazolyl)-pyrazolo[3,4-b]pyridines
    Patent number: 7960388
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: June 14, 2011
    Assignee: ChemoCentryx, Inc.
    Inventors: Lianfa Li, Andrew M.K. Pennell, Penglie Zhang
  • AZAINDAZOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20110098308
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: July 1, 2010
    Publication date: April 28, 2011
    Applicant: Chemocentryx, Inc.
    Inventors: Penglie Zhang, Andrew M.K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu, Mark M. Gleason, Yibin Zeng, Kevin Lloyd Greenman
  • Aryl sulfonamides
    Patent number: 7932252
    Abstract: The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: April 26, 2011
    Assignee: ChemoCentryx, Inc.
    Inventors: Solomon Ungashe, John Jessen Wright, Andrew Pennell
  • PYRROLIDINONE CARBOXAMIDE DERIVATIVES
    Publication number: 20110082172
    Abstract: Pyrrolidinone carboxamide compounds are provided that are useful for inhibiting the binding of ligands to the ChemR23 receptor.
    Type: Application
    Filed: September 21, 2010
    Publication date: April 7, 2011
    Applicant: ChemoCentryx, Inc.
    Inventors: Trevor T. Charvat, Hiufung Chu, Antoni Krasinski, Christopher W. Lange, Manmohan Reddy Leleti, Jay P. Powers, Sreenivas Punna, Timothy J. Sullivan, Solomon Ungashe
  • COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS
    Publication number: 20110052589
    Abstract: Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described.
    Type: Application
    Filed: June 11, 2010
    Publication date: March 3, 2011
    Applicant: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Bretton Summers, Maureen C. Howard, Thomas J. Schall
  • Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
    Patent number: 7884110
    Abstract: Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases and as controls in assays for the identification of CCR2 antagonists.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: February 8, 2011
    Assignee: ChemoCentryx, Inc.
    Inventors: Antoni Krasinski, Sreenivas Punna, Solomon Ungashe, Qiang Wang, Yibin Zeng
  • ARYL SULFONAMIDES
    Publication number: 20110021523
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: October 1, 2010
    Publication date: January 27, 2011
    Applicant: CHEMOCENTRYX, INC.
    Inventors: Solomon Ugashe, Zheng Wei, J.J. Wright, Andrew Pennell
  • MODULATORS OF CXCR7
    Publication number: 20110014121
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Application
    Filed: March 29, 2010
    Publication date: January 20, 2011
    Applicant: ChemoCentryx, Inc.
    Inventors: Xi Chen, Pingchen Fan, Mark M. Gleason, Juan C. Jaen, Lianfa Li, Jeffrey P. McMahon, Jay Powers, Yibin Zeng, Penglie Zhang
  • Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
    Patent number: 7871619
    Abstract: Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described.
    Type: Grant
    Filed: August 4, 2004
    Date of Patent: January 18, 2011
    Assignee: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Bretton Summers, Maureen C. Howard, Thomas J. Schall, Zhenhua Miao
  • N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES
    Publication number: 20100331302
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: July 8, 2010
    Publication date: December 30, 2010
    Applicant: Chemocentryx, Inc.
    Inventors: Trevor T. Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew M.K. Pennell, Edward J. Sullivan, William D. Thomas, Solomon Ungashe, Penglie Zhang, Jay Powers, Sreenivas Punna
  • MODULATORS OF CXCR7
    Publication number: 20100311712
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Application
    Filed: May 12, 2010
    Publication date: December 9, 2010
    Applicant: ChemoCentryx, Inc.
    Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Mark M. GLEASON, Juan C. JAEN, Lianfa LI, Jeffrey P. MCMAHON, Jay POWERS, Yibin ZENG, Penglie ZHANG, Junfa FAN
  • C5aR ANTAGONISTS
    Publication number: 20100311753
    Abstract: Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.
    Type: Application
    Filed: June 24, 2010
    Publication date: December 9, 2010
    Applicant: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Kevin Lloyd Greenman, Manmohan Reddy Leleti, Yandong Li, Jay P. Powers, Hiroko Tanaka, Ju Yang, Yibin Zeng
  • Substituted piperazines
    Patent number: 7842693
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: November 30, 2010
    Assignee: ChemoCentryx, Inc.
    Inventors: Andrew M. K. Pennell, James B. Aggen, J. J. Kim Wright, Subhabrata Sen, Brian E. McMaster, Daniel Joseph Dairaghi, Valeri V. Martichonok
  • REAGENTS THAT BIND CCX-CKR2
    Publication number: 20100278820
    Abstract: Antibodies that bind to CCX-CKR2 and methods of their use are provided.
    Type: Application
    Filed: January 21, 2010
    Publication date: November 4, 2010
    Applicant: ChemoCentryx, Inc.
    Inventors: Maureen Howard, Thomas Schall
  • Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
    Patent number: 7807704
    Abstract: The present invention is directed to novel compounds and pharmaceutical compositions that inhibit the binding of the SDF-1 chemokine to the chemokine receptor CXCR4 and/or the binding of the SDF-1 or I-TAC chemokines to the chemokine receptor CCXCKR2 (CXCR7). These compounds are useful in preventing tumor cell proliferation, tumor formation, metastasis, inflammatory diseases, treatment of HIV infectivity, treatment of stem cell differentiation and mobilization disorders, and ocular disorders.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: October 5, 2010
    Assignee: Chemocentryx, Inc.
    Inventors: William D. Thomas, Manmohan Reddy Leleti, Andrew M. K. Pennell
  • Methods and Compositions For Modulating Angiogenesis
    Publication number: 20100247540
    Abstract: The present invention provides method and compositions for modulating angiogenesis.
    Type: Application
    Filed: July 20, 2009
    Publication date: September 30, 2010
    Applicant: ChemoCentryx, Inc.
    Inventors: Jennifer Burns, Bretton Summers, Yu Wang, Maureen Howard, Thomas Schall, Zhenhua Miao
  • SUBSTITUTED PIPERAZINES
    Publication number: 20100240618
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: September 8, 2009
    Publication date: September 23, 2010
    Applicant: ChemoCentryx, Inc.
    Inventors: Andrew M.K. Pennell, James B. Aggen, J.J. Kim Wright, Subhabrata Sen, Brian E. McMaster, Daniel Joseph Dairaghi, Wei Chen, Penglie Zhang
  • BIS-ARYL SULFONAMIDES
    Publication number: 20100227902
    Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
    Type: Application
    Filed: May 14, 2010
    Publication date: September 9, 2010
    Applicant: CHEMOCENTRYX, INC.
    Inventors: Solomon Ungashe, Zheng Wei, J. J. Wright, Andrew Pennell, Brett Permack, Thomas Schall